Murray Mark Anthony 4
4 · Oyster Point Pharma, Inc. · Filed Nov 4, 2019
Insider Transaction Report
Form 4
Murray Mark Anthony
Director
Transactions
- Conversion
Series A Convertible Preferred Stock
2019-11-04−106,517→ 0 total→ Common Stock, par value $0.001 per share (106,517 underlying) - Conversion
Common Stock, par value $0.001 per share
2019-11-04+106,517→ 108,447 total
Footnotes (1)
- [F1]These shares of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, $0.001 par value per share ("Common Stock"), on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Series A Convertible Preferred Stock had no expiration date.